Today’s AI Top Pick: SPRO

7/15/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW8.6 / 107/15/2026

SPRO is the cleanest contrarian bounce setup in this pool: a fundamentally sound name (fund_score 8, PE 6.98, fwdPe 2.54, ROE 35.12, profit margin 27.82%, sales YoY +93.5%) that just got materially de-risked by a $105M royalty financing announced 7/14 — a hard positive catalyst arriving at the exact moment the chart is stretched to the downside. The 1d drawdown is -41.29% from the 21-bar high with position_in_21bar_range of just 0.7% — this is puked-out, not chased. Yet 1h/4h/1d forecasts all point up in unison: 1h fc_short/mid/long +35.87/+50.85/+57.61%, 4h +43.05/+52.41/+44.09%, 1d +17.35/+32.44/+26.08%. That is textbook multi-timeframe agreement into a washed-out tape. Bullish_prob is 1.0 and near_term_bullish is 1.0 (max), and RSI 28.46 confirms oversold. Analyst targetUpside is +135.3%. The one blemish is the 1wk mid/long forecast (-1.39/-14.83%), which I'm treating as noise from the pre-catalyst weekly bar — the funding deal fundamentally shifts the runway, so the weekly forecast is looking backward. Compared to QFIN (also fund_score 8, PE 2.27), SPRO has the fresher, more identifiable catalyst; QFIN was just downgraded on 7/03 and the 1wk short-term forecast is -1.78%. Waiting is the wrong move here because the catalyst is already public (7/14) and price is still pinned near range lows — the setup is early. If SPRO gaps into the day-2 post-catalyst window, entries above $1.80 will already reflect the news. Buying today at $1.65–1.75 puts you inside the base with a tight, well-defined risk level and gives you the full 20–35% forecast magnitude before you need to trim. Relative to the rest of the field: LESL, ALEC, RR, CHGG, LGCL have negative news landmines (GSK terminating the ALEC alliance, RR at fresh 52-wk lows, LGCL 142% short float). FABC just filed a 187M-share resale prospectus — dilution overhang. CANF and IMSR are strong runners-up but lack SPRO's combination of value fundamentals + fresh binary catalyst + max oversold reading.

Entry zone

$1.65–1.75 (current $1.71; scale in on any dip to $1.60)

Stop loss

$1.45 on a daily close (~-15%, below the 1d 21-bar low structure)

First target

$2.15–2.25 (matches 1d fc_mid +32% and prior support-turned-resistance)

Longer target

$2.60–2.85 (aligns with 4h fc_mid/long ~+50% and partial gap-fill toward pre-drawdown levels)

Risks

1wk forecast turns negative mid/long (-1.39% / -14.83%), suggesting the longer-cycle model still sees residual downside if catalyst euphoria fades
Small biotech, market cap only $98.4M — a 3–5% market drawdown could pull it below the $1.45 stop on illiquidity alone
Analyst recom is 3 (Hold), not Strong Buy — Street conviction lags the fundamentals; a follow-up downgrade could cap the bounce
Position 0.7% of 21-bar range on 1d means selling pressure has been relentless; a failed bounce that breaks $1.55 opens air down to prior lows
Short float 6.69% is modest — no squeeze fuel; this must move on organic buying from the royalty-deal thesis

Honorable mentions

QFINDeepest value in the pool: PE 2.27, fwdPe 2.82, ROE 21.22, profit margin 27.48%, targetUpside +77.1%, and forecasts across 4h/1d/1wk all sharply up (+28.97/+46.17/+72.79% long). Position in 21bar range is 0–14% across TFs — not chased. Only reason it isn't #1 is the 7/03 SeekingAlpha rating downgrade and 1wk fc_short of -1.78%, which suggest the model wants one more shake before ripping.

CANFFresh positive catalysts stack up: Phase 3 enrollment milestone (7/06), HC Wainwright PT raise to $8 (7/02), and pancreatic cancer survival data (7/01). 1wk fc_mid/long +523.65/+671.20% is aggressive but backed by multi-TF alignment. RSI 49 means it's not yet oversold — better as a BUY_PULLBACK than an immediate full-size entry.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	8.6	Fund_score 8 + fresh $105M royalty catalyst + max oversold (RSI 28.46, 0.7% range position) with 1h/4h/1d forecasts +17–57%.
2	QFIN	BUY NOW	8.1	Deep value (PE 2.27, ROE 21.22) with 1d/1wk forecasts +46/+73% long; slight caution on 7/03 downgrade but risk/reward asymmetric.
3	CANF	BUY NOW	7.4	Multiple positive catalysts (Phase 3 enrollment, PT raise) with 1wk fc_long +671% and all TFs bullish.
4	IMSR	BUY NOW	7.0	Molten-salt reactor narrative with $290M cash floor; 1d fc_long +89%, position low across 4h/1d, near_term_bullish 1.0.
5	OPTT	BUY NOW	6.8	European maritime security wins + RSI 28.8 + 1d/4h forecasts +75–99% long, targetUpside +650%.
6	BCDA	BUY PULLBACK	6.5	All TFs bullish with 1wk fc_long +282%, but micro-cap ($11.9M) and -100% sales YoY demand caution.
7	NEOV	BUY NOW	6.3	Sales YoY +324%, utility-scale pivot narrative, 4h/1d/1wk forecasts all positive; recent JV news constructive.
8	GTBP	BUY PULLBACK	5.7	Fund_score 4, all short-TF forecasts up (+7–35%), targetUpside +710%, but no revenue and micro-cap.
9	GLMD	BUY PULLBACK	5.6	Patent notice + restructured acquisition; 1d fc_long +135%, 1wk +898% — magnitudes silly but signal is up.
10	CNTN	BUY PULLBACK	5.4	Russell 3000 inclusion tailwind, 1d fc mid/long +21/+24%, but 1h at top of range (100%) — wait for a dip.
11	GNTA	WAIT	5.2	1wk fc_mid/long +209/+215% is compelling but 1h at 100% range position — chasing right here.
12	ATRA	WAIT	5.0	Fund_score 3.25 and 1wk fc_long +86.7%, but sales YoY -88.4% and near_term_bullish only 0.4.
13	TGEN	WAIT	4.8	$3.3M PO news good, but 1wk forecasts turn sharply negative (-35/-51%) and fair value was just cut.
14	EOSE	BUY PULLBACK	4.7	Truist Buy initiation + Frontier Power deal, but 1wk fc turns negative and recent capital raise pressured shares.
15	CALC	WAIT	4.4	FDA nod on Auxora is positive but $49M private placement is dilutive; 1wk fc_short -14.78%.
16	GRML	WAIT	4.2	SRX Global strategic investment supportive; 1wk fc_mid/long +362/+525% but 1wk fc_short -12.78% first.
17	ARQQ	WAIT	4.0	Lawsuit cleared but PS 299 is nosebleed; 1h/1wk forecasts near-flat, position 93.6% on 1h — chasing.
18	ANY	WAIT	3.9	DarkHorse crypto rebrand is speculative; 1d fc_long +155% but micro-float and no fundamentals support.
19	FLYX	WAIT	3.8	Jet.AI merger closed 7/07 — event risk digested; 1d fc_long +121% but structural post-deal uncertainty.
20	PROK	WAIT	3.7	Rilparencel accelerated path bullish but PS 526, profit margin -8131%; 1wk fc +36% modest given risk.
21	BTAI	WAIT	3.4	1wk fc_short/mid/long all -57.81%; long-cycle model outright bearish, negates 4h bounce forecast.
22	FABC	AVOID	3.0	187.2M-share resale prospectus (7/02) is a massive dilution overhang directly undercutting any bounce.
23	BIRD	WAIT	3.0	Allbirds → Smartbird rebrand + AI pivot narrative, but 4h/1wk fc weak and -74% year performance persists.
24	TROLL-USD	AVOID	2.9	1d fc_short/mid/long all -98.6% — model outright predicts collapse despite bullish flag.
25	GELS	WAIT	2.7	Micro-cap $5.68M, gross margin -869%, operMargin -4107%; forecast bounce not worth the balance-sheet risk.
26	LGCL	AVOID	2.3	Short interest 142.75% of float plus recent short-interest surge headline — quality of the setup is broken.
27	LESL	AVOID	2.0	'3 Reasons to Avoid LESL' headline plus -65.6% drawdown and fund_score -2.75 — broken trend, not a dip.
28	ALEC	AVOID	1.9	GSK terminated the brain-drug alliance (7/09) — pipeline reset, fundamental thesis blown up.
29	RR	AVOID	1.8	Just plummeted to 52-week lows (7/14); PS 75.74 and 1wk fc_long -39.7% — falling knife.
30	CHGG	AVOID	1.5	Two 'reasons to avoid' pieces this week + sales YoY -43.5% + recom 4 (Sell) — broken structurally.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord